Among the AML-pCT-MR subgroup with preceding BC, we noted a higher frequency of adverse risk categories (80.0%) (2022 ELN) and a higher frequency of the FLT3-ITD mutation (33.3%) compared to AML-pCT after BC. The gene discussed is FLT3; the disease is breast cancer.